Helen I Torley
Principal executive officer pay for Helen I Torley, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
HALOZYME THERAPEUTICS, INC. (HALO) FY2020–FY2025
Lagged peersTSR -35% vs peer group -1% over FY2020–FY2025
Paid for declineCAP $24,374,731→$39,731,590 while $100 invested went $240.89→$157.57 (FY2020–FY2025)
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2020 | $6.5M | $24.4M |
| FY2021 | $7.5M | $6.0M |
| FY2022 | $9.7M | $22.8M |
| FY2023 | $11.8M | -$3.6M |
| FY2024 | $12.7M | $20.7M |
| FY2025 | $23.2M | $39.7M |
The company's "$100 invested" index ran $240.89 at FY2020 → $157.57 by FY2025 — an annualized return of -8.1%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: -8.1%/yr at HALO ( FY2020–FY2025). See the CEO track-record ranking for context.